Announcements
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
- Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
- New partnership aims to advance vaccine against MERS coronavirus
- Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
- Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
- Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
More ▼
Key statistics
On Tuesday, Barinthus Biotherapeutics PLC (2AB:FRA) closed at 2.32, 54.67% above the 52 week low of 1.50 set on Sep 21, 2023.
52-week range
Open | 2.32 |
---|---|
High | 2.32 |
Low | 2.32 |
Bid | 1.88 |
Offer | 2.04 |
Previous close | 2.24 |
Average volume | 20.00 |
---|---|
Shares outstanding | 38.92m |
Free float | 37.22m |
P/E (TTM) | -- |
Market cap | 79.79m USD |
EPS (TTM) | -1.91 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 07:04 BST.
More ▼